Boehringer Ingelheim Corporation Release: New Pradaxa® Safety and Efficacy Data to be Featured at "Best of American Society of Hematology" Session
12/5/2012 10:40:16 AM
INGELHEIM, Germany--(BUSINESS WIRE)--The management of bleeding associated with the novel oral anticoagulants is one of the topics of interest at this year’s annual meeting of the American Society of Hematology. Important new data from the RE-LY® trial and pooled results from five Phase III studies will be presented, which compare the management and outcomes for Pradaxa® (dabigatran etexilate) and warfarin treatments.1 The data will provide insights into the prognosis of anticoagulated patients in case a major bleed should occur. The new data will be presented on December 8th at the ASH Annual Meeting and Exposition in Atlanta, Georgia, USA and are additionally featured in ‘The Best of ASH’ session, highlighting it among numerous clinical reports presented at the scientific meeting.